Day: January 25, 2022

PSYC to Enter Multi-Million Dollar Mental Health App Market Under New Partnership with Digital Acorn, Ltd. LAKE OSWEGO, OR, Jan. 25, 2022 (GLOBE NEWSWIRE) — Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) a media leader for the emerging medicinal psychedelics sector, and authorities behind Psychedelic Spotlight, a top ranking psychedelic news and information platform, is pleased to announce that based on recent updates tied to the controlling interest of PsycheDev, Inc. (“PsycheDev”), PSYC is now a 50% equity stakeholder in the digital mental wellness platform and has recently entered into co-development partnership with Digital Acorn Ltd. (“Digital Acorn”), a private investment group focused on early stage and emerging growth companies. In January of 2021, PSYC entered a Joint Venture Partnership...

Austin, TX, Jan. 25, 2022 (GLOBE NEWSWIRE) — QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases, today announces the appointment of Adriann Sax to the QSAM Biosciences Board of Directors. Ms. Sax will serve on the Company’s Audit Committee and will chair the Nomination and Governance Committee. Ms. Sax has a distinguished 30+ year career in biotech and life sciences, serving in leadership, operational and business development roles with a focus on oncology for both Fortune 100 and start-up companies. She currently serves as CEO and co-founder of Vetigenics LLC, an animal health biotech company, where she has secured partnerships with Merck, obtained federal grants, and which was named...

CARSON CITY, NV, Jan. 25, 2022 (GLOBE NEWSWIRE) — via NewMediaWire -– Anything Technologies Media Inc. (EXMT) (Alternative Wellness Health), announced today that the joint venture negotiations with a major THC Licensed and grow organization expects to be concluded soon and the joint venture should be completed by the end of January. Orders for both the Licensed Cannabis Water and CBD beverages expect to be processed and manufactured at our facility in February. We anticipate working with our distribution channels which will include California distributors for the Cannabis Water and a multi-state rollout for our CBD Beverages. As previously stated, this joint venture will allow access to 6 distributors and over 1000 dispensaries in the CBD and Cannabis market. Our multi-state CBD Water distribution model will include California,...

BMF-219 is the first irreversible covalent menin inhibitor to enter the clinic Phase I trial is enrolling patients with relapsed/refractory acute leukemias, including those with MLL1/KMT2A gene rearrangements or NPM1 mutations Phase I trial is expected to include up to 20 clinical sites at leading US medical centersREDWOOD CITY, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), today announced that the first patient has been dosed in its Phase I clinical trial evaluating BMF-219, the company’s irreversible covalent menin inhibitor, in patients with relapsed/refractory (r/r) acute leukemias, including those with MLL1/KMT2A gene rearrangements or NPM1 mutations. “We are honored and deeply humbled by this significant milestone, which marks our successful transition to a clinical stage company....

By iteratively analyzing and reporting on real-world data, life sciences organizations can quickly assess multiple market opportunities during therapy development FRAMINGHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the availability of Latitude Discovery, a new product aimed at pre-commercial biopharma and medical device companies. With Latitude Discovery, users can quickly perform iterative analysis of real-world data to assess and size potential market opportunities associated with therapy development for granular patient cohorts. Latitude Discovery is purposefully designed to meet the needs of pre-commercial pharmaceutical, biotechnology and medical device companies who are looking to bring new treatments to market. With...

MONTREAL, Jan. 25, 2022 (GLOBE NEWSWIRE) — Earth Alive Clean Technologies Inc. (TSXV: EAC – “Earth Alive” or the “Company”) announced today that Jean-Luc Deschamps, CPA, CA has resigned as Chief Financial Officer to focus on his other professional activities and will be leaving the Corporation on March 25, 2022 giving the time to finalize the year-end financial statements while the Corporation initiates the search for a full time replacement CFO. Mr. Nikolaos Sofronis, Chief Executive Officer of the Board of Earth Alive commented, “I would like to thank Mr. Deschamps for his contribution during his time with the Corporation and wish him success in his future endeavours”. About Earth Alive Clean TechnologiesEarth Alive is a soil health company and an industry leader in microbial technologies. Earth Alive’s innovative products contribute...

DUBLIN, Ireland, Jan. 25, 2022 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the results of an Extraordinary General Meeting (EGM). EGM Results As previously announced, the Company has entered into refinancing transactions (the “Refinancing”) with respect to substantially all of the outstanding $99.9 million of exchangeable senior notes issued by our subsidiary, Trinity Biotech Investment Limited, and guaranteed by the Company. The Refinancing is conditional on, among other things, the approval by the Company’s shareholders of the new term loan, an increase in the authorized share capital of the Company, authority for the board to issue ordinary shares of the Company without limitation under...

Microchip’s alternatives to inflexible hybrid-style converters improve design flexibility while reducing system size, cost, and development time CHANDLER, Ariz., Jan. 25, 2022 (GLOBE NEWSWIRE) — Space system designers cannot easily support non-standard voltages or add functions with traditional hybrid-style power converters. Microchip Technology Inc. (Nasdaq: MCHP) has eliminated the cost, complexity and customization challenges of these hybrid solutions by offering a discrete-component-based, space-grade DC-DC power converter family that now includes 28V-input, 50-watt (W) radiation-tolerant options. “Our latest 28V-input SA50-28 products greatly simplify and accelerate system development,” said Leon Gross, vice president of Microchip’s discrete product business unit. “They are easier to customize than alternative space-grade...

NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) — Perella Weinberg Partners (Nasdaq: PWP), a leading global independent advisory firm, today announced the promotion of four Managing Directors to Partners of the Firm, effective January 1, 2022:Jérôme Brassart – London Nikhil Menon – New York Mauro Rossi – New York Lisa Saski – New York“We are thrilled to announce the promotions of Jérôme, Nikhil, Mauro and Lisa to Partner, reflecting the excellence and integrity of their work, valuable contributions to strategically important areas of our business and unwavering commitment to our firm, our mission and our clients,” said Peter Weinberg, Chief Executive Officer of PWP. “It is particularly rewarding to promote our colleagues from within who exemplify PWP’s mission and culture of collaboration and intensity, and we look forward to their...

Outlook Therapeutics advancing first ever ophthalmic formulation of bevacizumab towards new U.S. FDA Biologics License Application (BLA) submission, anticipated this quarterONS-5010 / LYTENAVA™ (bevacizumab-vikg) expected to receive, if approved, 12 years of regulatory exclusivity in the U.S. estimated $13 billion global ophthalmic anti-VEGF market Strong balance sheet to support the Company’s expected capital needs through the anticipated approval of the ONS-5010 BLA expected in the first calendar quarter of 2023ISELIN, N.J., Jan. 25, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today provided a business outlook for 2022. “The past twelve months have been...